| Title |
Combination chemotherapy for primary treatment of high‐risk gestational trophoblastic tumour
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2013
|
| DOI | 10.1002/14651858.cd005196.pub4 |
| Pubmed ID | |
| Authors |
Linyu Deng, Jing Zhang, Taixiang Wu, Theresa A Lawrie |
| Abstract |
This is an update of the original review that was published in The Cochrane Database of Systematic Reviews, 2009, Issue 2. Gestational trophoblastic neoplasia (GTN) are malignant disorders of the placenta that include invasive hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT). Choriocarcinoma and invasive hydatidiform mole respond well to chemotherapy: low-risk tumours are treated with single-agent chemotherapy (e.g. methotrexate or actinomycin D), whereas high-risk tumours are treated with combination chemotherapy (e.g. EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine)). Various drug combinations may be used for high-risk tumours; however, the comparative efficacy and safety of these regimens is not clear. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 176 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 174 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 22 | 13% |
| Student > Master | 18 | 10% |
| Other | 16 | 9% |
| Researcher | 16 | 9% |
| Student > Postgraduate | 11 | 6% |
| Other | 32 | 18% |
| Unknown | 61 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 68 | 39% |
| Nursing and Health Professions | 15 | 9% |
| Psychology | 6 | 3% |
| Agricultural and Biological Sciences | 3 | 2% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Other | 16 | 9% |
| Unknown | 65 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 April 2013.
All research outputs
#16,106,935
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#10,216
of 11,499 outputs
Outputs of similar age
#180,347
of 291,268 outputs
Outputs of similar age from Cochrane database of systematic reviews
#120
of 163 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,268 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 163 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.